Astrazeneca (AZN) Finished Goods (2016 - 2025)

Astrazeneca has reported Finished Goods over the past 11 years, most recently at $1.9 billion for Q4 2025.

For Q4 2025, Finished Goods rose 26.76% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 26.76%, while the annual FY2025 figure was $1.9 billion, 26.76% up from the prior year.
Finished Goods for Q4 2025 was $1.9 billion at Astrazeneca, up from $1.5 billion in the prior quarter.
Over five years, Finished Goods peaked at $2.0 billion in Q4 2021 and troughed at $1.4 billion in Q4 2022.
A 5-year average of $1.7 billion and a median of $1.6 billion in 2023 define the central range for Finished Goods.
Biggest five-year swings in Finished Goods: surged 40.6% in 2021 and later decreased 29.77% in 2022.
Year by year, Finished Goods stood at $2.0 billion in 2021, then fell by 29.77% to $1.4 billion in 2022, then rose by 10.97% to $1.6 billion in 2023, then decreased by 3.25% to $1.5 billion in 2024, then increased by 26.76% to $1.9 billion in 2025.
Business Quant data shows Finished Goods for AZN at $1.9 billion in Q4 2025, $1.5 billion in Q4 2024, and $1.6 billion in Q4 2023.

Peer Comparison